HUB Organoids predict patient response to treatment.
Our patented technology allows the development of patient-derived “mini-organs in a dish” from both healthy and diseased tissues to close the gap between the lab and the clinic.
De-risk Clinical Investment and Optimize Portfolio Returns with HUB Organoids
Reduce drug attrition and predict patient response with our preclinical services and clinical trials in a dish
Link
Decipher the complexity of the human disease with our custom model and assay development services
Link
Bring HUB Organoid Technology and knowhow in-house
Link
by bringing next-generation therapeutics to patients
|
Bring HUB Organoid Technology and knowhow in-house
|
Outsource your drug development program
|
Make mCRC drug decisions with patient-relevant biology—before you commit to the clinic.
Predict therapeutic effects of antibody-drug conjugates (ADCs) with patient-specific organoid models.
Clinically-relevant models to test efficacy and study resistance mechanisms.
